Olema Pharmaceuticals Inc (OLMA) is a Healthcare · Biotechnology company listed on NASDAQ. Price $9.82 (-0.81%), Market cap $1.22B, 52-week low–high $4.01 ~ $35.83.
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alp
Financial statements, price targets, institutional (13F) holdings and related news for Olema Pharmaceuticals Inc are updated in real time on BlackAll Trade.
Olema Pharmaceuticals Inc trades at $9.82 (-0.81%). Real-time quotes and charts are available on BlackAll Trade.
Olema Pharmaceuticals Inc has a market cap of about $1.22B.
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candi